Journal: Neuropsychiatric Disease and Treatment

Article Title: Exosomes Regulate the NLRP3/Caspase-1/IL-1β Signaling Pathway in Parkinson’s Disease: Mechanisms of Neuroinflammation Modulation and α-Synuclein Propagation

doi: 10.2147/NDT.S587802

Figure Lengend Snippet: Dual Roles of Exosomes in Parkinson’s Disease Mediating Neuroinflammation vs Neuroprotection. Top Left (Vicious Cycle): The red-shaded region depicts the neurodegenerative feedback loop. Damaged Dopaminergic Neurons (left) exhibiting mitochondrial fragmentation release lipid vesicles containing α-synuclein oligomers (depicted as red clusters). These vesicles are internalized by Activated Microglia (M1 phenotype, Orange cell), triggering the assembly of NLRP3 inflammasomes (spoked wheel structures). The microglia subsequently release exosomes containing these inflammasomes and pro-inflammatory cytokines (eg, IL-1β, shown as red spiky spheres), which cycle back to further damage the neuron, inducing the formation of double-membraned autophagosomes. Bottom Right (Therapeutic Intervention): The blue-shaded region illustrates the protective mechanism. Mesenchymal Stem Cells (MSCs) or Astrocytes (teal cell) secrete Therapeutic Exosomes (blue vesicles). These exosomes are loaded with protective cargo, specifically microRNA-146a (miR-146a) (green strands) and Growth Factors such as BDNF (green rods). Upon uptake by the dopaminergic neuron, these factors restore mitochondrial health and interrupt the apoptotic pathway. Bold text: Highlights critical cell types (eg, Activated Microglia, Macrophage) and key molecular components (eg, NLRP3, NF-κB) central to the pathway; Red/Orange text and structures: Indicate pathological elements, pro-inflammatory cytokines, and damaged cellular states (eg, Damaged \α-syn, Mitochondrial Dysfunction); Arrows (→): Indicate the directional flow of exosomes and the sequence of signal transduction events (eg, Priming → Activation); Horizontal line (—): explanatory function.

Article Snippet: Studies have demonstrated that PEGylated liposome-encapsulated MSC-derived exosomes exhibit an 8-fold increase in intracerebral uptake compared with free exosomes and can reduce NLRP3 inflammation in the substantia nigra by 70%., Exosome delivery enhancement can address the key issue of low exosome brain delivery efficiency; however, the long-term safety of nanocarriers requires evaluation.

Techniques: Sequencing, Transduction, Activation Assay

Journal: Neuropsychiatric Disease and Treatment

Article Title: Exosomes Regulate the NLRP3/Caspase-1/IL-1β Signaling Pathway in Parkinson’s Disease: Mechanisms of Neuroinflammation Modulation and α-Synuclein Propagation

doi: 10.2147/NDT.S587802

Figure Lengend Snippet: Immune Cell Exosomes mediated NLRP3 inflammatory cycle in Parkinson’s disease. Bold text: Highlights critical cell types (eg, Activated Microglia, Macrophage) and key molecular components (eg, NLRP3, NF-κB) central to the pathway; Red and Orange text and structures: Indicate pathological elements, pro-inflammatory cytokines, and damaged cellular states (eg, Damaged \α-syn, Mitochondrial Dysfunction); The red dots near macrophages are inflammatory factors, such as TNF - α; Arrows (→): Indicate the directional flow of exosomes and the sequence of signal transduction events (eg, Priming → Activation); Horizontal line (—): explanatory function.

Article Snippet: Studies have demonstrated that PEGylated liposome-encapsulated MSC-derived exosomes exhibit an 8-fold increase in intracerebral uptake compared with free exosomes and can reduce NLRP3 inflammation in the substantia nigra by 70%., Exosome delivery enhancement can address the key issue of low exosome brain delivery efficiency; however, the long-term safety of nanocarriers requires evaluation.

Techniques: Sequencing, Transduction, Activation Assay

Journal: Neuropsychiatric Disease and Treatment

Article Title: Exosomes Regulate the NLRP3/Caspase-1/IL-1β Signaling Pathway in Parkinson’s Disease: Mechanisms of Neuroinflammation Modulation and α-Synuclein Propagation

doi: 10.2147/NDT.S587802

Figure Lengend Snippet: Therapeutic Interventions Targeting the Exosome-NLRP3 Aixs in Parkinson’s Disease. Top Panel (Stem Cell Therapy): Mesenchymal Stem Cells (MSCs) and Astrocytes are utilized to secrete therapeutic exosomes. These vesicles are naturally enriched with miR-146a (genetic regulator) and BDNF (Brain-Derived Neurotrophic Factor), which are transferred to recipient cells to promote survival and anti-inflammatory states. Left Panel (Chemical Inhibition): The pharmacological agent GW4869 is depicted inhibiting the exosomal secretory machinery of pro-inflammatory M1 Microglia. This blockade prevents the release of “MDEs” (Microglial-Derived Exosomes) carrying toxic α-synuclein and NLRP3 inflammasome components. Right Panel (Engineering & Loading): Engineered exosomes are modified with surface Transferrin Receptor (TfR) Antibodies (Y-shaped markers) to facilitate transport across the Blood-Brain Barrier (BBB). These vesicles serve as delivery vehicles for siRNA and MCC950 (a specific NLRP3 inhibitor) to directly target microglial inflammation. Bottom Panel (Gut-Brain Regulation): Probiotics are used to modulate the intestinal environment, strengthening the gut barrier and reducing the release of Lipopolysaccharide (LPS)-associated exosomes into the Gut-Brain Axis. Center Panel (Recovery Zone): The cumulative effect of these interventions is the promotion of a Healing Neuron phenotype (characterized by restored mitochondrial function and enhanced autophagy) and the repolarization of microglia to the protective Resting (M2) phenotype. Bold text: Indicates specific biological structures, molecules, or labels explicitly visible in the figure; Blue and Green text elements: Correspond to therapeutic agents (eg, “miR-146a”, “BDNF”) and neuroprotective states (eg, “Healing Neuron”) depicted in cool tones in the diagram; Red and Orange text elements: Correspond to pathological drivers (eg, “LPS”, “α-syn”) and inflammatory states (eg, “M1 Microglia”) depicted in warm tones in the diagram; Arrows (→): Indicate promotion, secretion, or transfer pathways; T-bars (T): Indicate inhibition or suppression of a pathway; Red Cross (×): Indicates the blockage or prohibition of a pathological process.

Article Snippet: Studies have demonstrated that PEGylated liposome-encapsulated MSC-derived exosomes exhibit an 8-fold increase in intracerebral uptake compared with free exosomes and can reduce NLRP3 inflammation in the substantia nigra by 70%., Exosome delivery enhancement can address the key issue of low exosome brain delivery efficiency; however, the long-term safety of nanocarriers requires evaluation.

Techniques: Derivative Assay, Inhibition, Modification, Probiotics